woman browsing through medical products and reading the label on a bottle of medicine

EY advisors to FrostPharma in their new partnership with Priveq

The Swedish entrepreneurial specialty pharma company FrostPharma welcomes Priveq as a new growth partner.

FrostPharma, specializing in commercialization of value-adding medicines and climate impact healthcare consumables, welcomes Priveq as a new growth partner.

Based in Stockholm, Sweden, FrostPharma signed its first product agreements in 2017 and has since then launched over 50 products. The partnership with Priveq will provide FrostPharma with opportunities for accelerated sustainable growth going forward.

EY Corporate Finance team in Health, Sciences & Wellness acted as financial advisers to the owners of FrostPharma. The M&A team consisted of Staffan Folin (Engagement Partner), Victor Svensson (Engagement Manager), Ellen Daver and Henrik Nordlander.

Learn more in this press release. To explore EY’s recent transactions click here and you find our Health Sciences & Wellness specific insights here. You can also sign up to our newsletter lists through our preference center.

Related deal alerts

    Summary

    EY Corporate Finance team in Health, Sciences & Wellness acted as financial advisers to the owners of FrostPharma. We are very pleased to be involved in this specialty pharma deal and look forward to supporting more transactions within this sector.

    About this article

    Authors